Novo Nordisk As Stock Net Income
| NONOF Stock | USD 50.75 2.66 5.53% |
As of the 10th of February, Novo Nordisk secures the Risk Adjusted Performance of 0.041, downside deviation of 4.25, and Mean Deviation of 2.96. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Novo Nordisk AS, as well as the relationship between them. Please verify Novo Nordisk AS jensen alpha, potential upside, as well as the relationship between the Potential Upside and skewness to decide if Novo Nordisk AS is priced some-what accurately, providing market reflects its recent price of 50.75 per share. Given that Novo Nordisk AS has jensen alpha of 0.0248, we recommend you to check Novo Nordisk's last-minute market performance to make sure the company can sustain itself at a future point.
Novo Nordisk's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Novo Nordisk's valuation are provided below:Novo Nordisk AS does not presently have any fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Novo |
Novo Nordisk 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Novo Nordisk's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Novo Nordisk.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Novo Nordisk on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Novo Nordisk AS or generate 0.0% return on investment in Novo Nordisk over 90 days. Novo Nordisk is related to or competes with Rocket Pharmaceuticals, Aura Biosciences, Annexon, Solid Biosciences, Larimar Therapeutics, Altimmune, and Autolus Therapeutics. Novo Nordisk AS, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutica... More
Novo Nordisk Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Novo Nordisk's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Novo Nordisk AS upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.25 | |||
| Information Ratio | 0.0173 | |||
| Maximum Drawdown | 27.29 | |||
| Value At Risk | (5.56) | |||
| Potential Upside | 7.09 |
Novo Nordisk Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Novo Nordisk's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Novo Nordisk's standard deviation. In reality, there are many statistical measures that can use Novo Nordisk historical prices to predict the future Novo Nordisk's volatility.| Risk Adjusted Performance | 0.041 | |||
| Jensen Alpha | 0.0248 | |||
| Total Risk Alpha | (0.29) | |||
| Sortino Ratio | 0.0168 | |||
| Treynor Ratio | 0.1046 |
Novo Nordisk February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.041 | |||
| Market Risk Adjusted Performance | 0.1146 | |||
| Mean Deviation | 2.96 | |||
| Semi Deviation | 4.04 | |||
| Downside Deviation | 4.25 | |||
| Coefficient Of Variation | 2431.23 | |||
| Standard Deviation | 4.13 | |||
| Variance | 17.03 | |||
| Information Ratio | 0.0173 | |||
| Jensen Alpha | 0.0248 | |||
| Total Risk Alpha | (0.29) | |||
| Sortino Ratio | 0.0168 | |||
| Treynor Ratio | 0.1046 | |||
| Maximum Drawdown | 27.29 | |||
| Value At Risk | (5.56) | |||
| Potential Upside | 7.09 | |||
| Downside Variance | 18.06 | |||
| Semi Variance | 16.29 | |||
| Expected Short fall | (3.12) | |||
| Skewness | (0.53) | |||
| Kurtosis | 3.01 |
Novo Nordisk AS Backtested Returns
At this point, Novo Nordisk is very steady. Novo Nordisk AS has Sharpe Ratio of 0.0307, which conveys that the firm had a 0.0307 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Novo Nordisk, which you can use to evaluate the volatility of the firm. Please verify Novo Nordisk's Mean Deviation of 2.96, downside deviation of 4.25, and Risk Adjusted Performance of 0.041 to check out if the risk estimate we provide is consistent with the expected return of 0.13%. Novo Nordisk has a performance score of 2 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 1.53, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Novo Nordisk will likely underperform. Novo Nordisk AS right now secures a risk of 4.19%. Please verify Novo Nordisk AS skewness, and the relationship between the potential upside and rate of daily change , to decide if Novo Nordisk AS will be following its current price movements.
Auto-correlation | -0.12 |
Insignificant reverse predictability
Novo Nordisk AS has insignificant reverse predictability. Overlapping area represents the amount of predictability between Novo Nordisk time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Novo Nordisk AS price movement. The serial correlation of -0.12 indicates that less than 12.0% of current Novo Nordisk price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.12 | |
| Spearman Rank Test | -0.05 | |
| Residual Average | 0.0 | |
| Price Variance | 26.25 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Novo Nordisk AS reported net income of 55.52 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The net income for all United States stocks is significantly lower than that of the firm.
Novo Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novo Nordisk's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Novo Nordisk could also be used in its relative valuation, which is a method of valuing Novo Nordisk by comparing valuation metrics of similar companies.Novo Nordisk is currently under evaluation in net income category among its peers.
Novo Fundamentals
| Return On Equity | 0.72 | |||
| Return On Asset | 0.22 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.43 % | |||
| Current Valuation | 292.82 B | |||
| Shares Outstanding | 1.72 B | |||
| Shares Owned By Institutions | 38.87 % | |||
| Price To Earning | 41.24 X | |||
| Price To Book | 26.64 X | |||
| Price To Sales | 1.73 X | |||
| Revenue | 176.95 B | |||
| Gross Profit | 148.51 B | |||
| EBITDA | 76.8 B | |||
| Net Income | 55.52 B | |||
| Cash And Equivalents | 31.04 B | |||
| Cash Per Share | 13.68 X | |||
| Total Debt | 20.77 B | |||
| Debt To Equity | 0.34 % | |||
| Current Ratio | 0.94 X | |||
| Book Value Per Share | 37.10 X | |||
| Cash Flow From Operations | 78.89 B | |||
| Earnings Per Share | 3.53 X | |||
| Price To Earnings To Growth | 1.94 X | |||
| Number Of Employees | 54.39 K | |||
| Beta | 0.33 | |||
| Market Capitalization | 318.05 B | |||
| Total Asset | 241.26 B | |||
| Retained Earnings | 41.06 B | |||
| Working Capital | 9.98 B | |||
| Current Asset | 51.58 B | |||
| Current Liabilities | 41.59 B | |||
| Z Score | 9.0 | |||
| Annual Yield | 0.01 % | |||
| Five Year Return | 1.78 % | |||
| Net Asset | 241.26 B | |||
| Last Dividend Paid | 12.4 |
About Novo Nordisk Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novo Nordisk AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novo Nordisk using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novo Nordisk AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Additional Information and Resources on Investing in Novo Pink Sheet
When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..